Longitudinal assessment of lipid and hepatic clinical parameters in workers involved with the demolition of perfluoroalkyl manufacturing facilities

Journal of Occupational and Environmental Medicine

Volumn 54, Issue 8, 2012, Pages 974-983

  Olsen, Geary W ^a   Ehresman, David J ^a   Buehrer, Betsy D ^a   Gibson, Barbara A ^a   Butenhoff, John L ^a   Zobel, Larry R ^a  

^a 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PERFLUOROOCTANESULFONIC ACID; PERFLUOROOCTANOIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; CHEMICAL INDUSTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL CHEMISTRY; CONTROLLED STUDY; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; WORK ENVIRONMENT;

ADULT; ALKANESULFONIC ACIDS; CAPRYLATES; CHEMICAL INDUSTRY; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; FLUOROCARBONS; HUMANS; LIPIDS; LIPOPROTEINS, HDL; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE;

EID: 84865530319     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0b013e31825461d2     Document Type: Article

References (42)

1. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 2010;118:197-202.
2. Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents. Arch Pediatr Adolesc Med. 2010;164:860-869.
3. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009;170:1268-1278.
4. Kato K, Wong LY, Jia LT, Kuklenyik Z, Calafat AM. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ Sci Technol. 2011;45:8037-8045.
5. Steenland K, Fletcher T, Savitz DA. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect. 2010;119:1100-1108.
6. Emmett EA, Zhang H, Shofer FS, et al. Community exposure to perfluorooctanoate: relationships between serum levels and certain health parameters. J Occup Environ Med. 2006;48:771-779. (Pubitemid 44221831)
7. Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med. 2007;49:1086-1096. (Pubitemid 350287341)
8. Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med. 2007;49:872-879. (Pubitemid 47254709)
9. Olsen GW, Burris JM, Burlew MM, Mandel JH. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med. 2003;45:260-270. (Pubitemid 36343227)
10. Olsen GW, Zobel LR. 2007. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health. 2007;81:231-246. (Pubitemid 47617455)
11. Costa G, Sartori S, Consonni D. Thirty years of medical surveillance in perfluorooctanoic acid production workers. J Occup Environ Med. 2009;51:364-372.
12. Olsen GW, Burris JM, Burlew MM, Mandel JH. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol. 2000;23:603-620.
13. Elcombe CR, Elcombe BM, Foster JR, et al. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARα and CAR/PXR. Arch Toxicol. 2010;84:787-798.
14. Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, Butenhoff JL. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology. 2012;293:16-29.
15. Bjork JA, Wallace KB. Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures. Toxicol Sci. 2009;111:89-99.
16. Bjork JA, Butenhoff JL, Wallace KB. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology. 2011;288:8-18.
17. Kuklenyik Z, Reich JA, Tully JS, Needham LL, Calafat AM. Automated solidphase extraction and measurement of perfluorinated organic acids and amides in human serum and milk. Environ Sci Technol. 2004;38:3698-3704. (Pubitemid 38879911)
18. Ehresman DJ, Froehlich JW, Olsen GW, Chang SC, Butenhoff JL. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ Res. 2007;103:176-184. (Pubitemid 46123314)
19. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perflurohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115:1298-1305. (Pubitemid 47471253)
20. Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect. 2010;118:222-228.
21. Hölzer J, Göen T, Rauchfuss K, et al. One-year follow-up of perfluorinated compounds in plasma of German residents from Arnsberg formerly exposed to PFOA contaminated drinking water. Int J Hyg Environ Health. 212:499-504.
22. Château-Degat ML, Pereg D, Dallaire R, Ayotte P, Dery S, Dewailly E. Effects of perfluorooctanesulfonate exposure on plasma lipid levels in the Inuit population of Nunavik (Northern Quebec). Environ Res. 2010;110:710-717.
23. Pinney SM, Biro FM, Herrick R, et al. Exposure to perfluorooctanoic acid (PFOA) and plasma lipid concentrations in young girls. Abstract P54. PFAA Days III. US EPA ORD, June 2010.
24. Patel CJ, Cullen MR, Ioannidis JPA, et al. Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels. Int J Epidemiol. 2012 Mar 15. [Epub ahead of print] doi:10.1093/ije/dys003.
25. Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol. 2000;40:616-623.
26. Pelkonen R, Fogelholm R, Nikkila EA. Increase in serum cholesterol during phenytoin treatment. Br Med J. 1975;4:85.
27. Olsen GW, Burlew MM, Marshall JC, Burris JM, Mandel JH. Analysis of episodes of care in a perflurooctanesulfonyl fluoride production facility. J Occup Environ Med. 2004;46:837-846. (Pubitemid 39093775)
28. Lundin JI, Alexander BH, Olsen GW, Church TR. Ammonium perfluorooctanoate production and occupational mortality. Epidemiology. 2009;20:921-928.
29. Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS. Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup Environ Med. 2003;60:722-729. (Pubitemid 37203427)
30. Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol. 2008;18:15-22. (Pubitemid 350184346)
31. Sakr CJ, Symons JM, Kreckmann KH, Leonard RC. Ischaemic heart disease mortality study among workers with occupational exposure to ammonium perfluorooctanoate. Occup Environ Med. 2009;66:699-703.
32. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580. (Pubitemid 43326861)
33. Curran I, Hierlihy SL, Liston V, et al. Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). J Toxicol Environ Health A. 2008;71:1526-1541.
34. Elcombe CR, Elcombe BM, Foster JR, et al. Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to 84 days following seven days of dietary exposure to potassium perfluorooctanesulfonate. Toxicology. 2012;293:30-40.
35. Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci. 2002;68:249-264. (Pubitemid 34785246)
36. *3 Leiden. CETP mice. Toxicol Sci. 2011;123:290-303.
37. Macpherson IR, Bissett D, Petty RD, et al. A first-in-human phase I clinical trial of CXR1002 in patients with advanced cancer. J Clin Oncol. 2011;29:3063.
38. Butenhoff J, Costa G, Elcombe C, et al. 2002. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci. 2002;69:244-257.
39. Butenhoff JL, Pieterman EJ, Ehresman DJ, et al. Distribution of perfluorooctanesulfonate and perfluorooctanoate into human plasma lipoprotein fractions. Toxicol Lett. 2012;210:360-365.
40. Lin CY, Lin LY, Chiang CK, et al. Investigation of the association between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol. 2010;105:1354-1363.
41. Melzer D, Rice N, Depledge MH, Henley WE, Galloway TS. Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ Health Perspect. 2010;118:686-692.
42. Gallo V, Leonardi G, Genser B, Lopez-Espinosa MJ, et al. Serum perfluorocatanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentratons and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect. 2012. http://doi.org/10.1289/ehp.1104436. Accessed January 30, 2012.